Palisade Bio (NASDAQ:PALI) Upgraded by Wall Street Zen to “Hold” Rating

Palisade Bio (NASDAQ:PALI) was upgraded by stock analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a research note issued to investors on Sunday.

Other analysts have also issued reports about the company. Oppenheimer set a $7.00 target price on Palisade Bio in a research report on Tuesday. Weiss Ratings upgraded Palisade Bio from a “sell (e+)” rating to a “sell (d-)” rating in a report on Monday, June 29th. HC Wainwright reissued a “buy” rating and issued a $2.00 price objective on shares of Palisade Bio in a research note on Tuesday. LADENBURG THALM/SH SH upgraded Palisade Bio to a “strong-buy” rating in a report on Thursday, June 25th. Finally, Wolfe Research started coverage on Palisade Bio in a report on Thursday, April 9th. They set an “outperform” rating and a $7.00 price objective for the company. Two analysts have rated the stock with a Strong Buy rating, six have given a Buy rating and one has given a Sell rating to the company. According to MarketBeat, the company presently has an average rating of “Buy” and an average target price of $8.83.

Palisade Bio Stock Performance

Shares of Palisade Bio stock opened at $2.10 on Friday. The firm has a market capitalization of $364.52 million, a PE ratio of -2.08 and a beta of 1.50. Palisade Bio has a 1 year low of $0.53 and a 1 year high of $2.85. The firm’s 50 day moving average is $1.92 and its 200 day moving average is $1.91.

Palisade Bio (NASDAQ:PALI) last posted its quarterly earnings results on Tuesday, May 12th. The company reported ($0.05) earnings per share for the quarter, missing the consensus estimate of ($0.04) by ($0.01). As a group, research analysts anticipate that Palisade Bio will post -0.25 earnings per share for the current year.

Institutional Investors Weigh In On Palisade Bio

A number of institutional investors and hedge funds have recently bought and sold shares of PALI. CTC Alternative Strategies Ltd. purchased a new position in Palisade Bio in the first quarter worth $31,000. Bank of America Corp DE increased its position in shares of Palisade Bio by 181.1% during the 1st quarter. Bank of America Corp DE now owns 197,074 shares of the company’s stock valued at $345,000 after purchasing an additional 126,977 shares during the last quarter. Janus Henderson Group PLC increased its position in shares of Palisade Bio by 1.4% during the 1st quarter. Janus Henderson Group PLC now owns 10,689,452 shares of the company’s stock valued at $18,760,000 after purchasing an additional 149,118 shares during the last quarter. ADAR1 Capital Management LLC increased its position in shares of Palisade Bio by 13.0% during the 1st quarter. ADAR1 Capital Management LLC now owns 2,264,845 shares of the company’s stock valued at $3,963,000 after purchasing an additional 260,000 shares during the last quarter. Finally, Orbimed Advisors LLC raised its stake in shares of Palisade Bio by 24.7% during the 1st quarter. Orbimed Advisors LLC now owns 2,333,000 shares of the company’s stock worth $4,083,000 after purchasing an additional 461,580 shares during the period. 11.79% of the stock is owned by hedge funds and other institutional investors.

Palisade Bio Company Profile

Palisade Bio, Inc is a clinical‐stage biotechnology company focused on pioneering localized immunotherapies for the treatment of cancer and inflammatory diseases. The company leverages a proprietary prodrug platform designed to activate therapeutic agents selectively within the tumor microenvironment or sites of inflammation. Its core strategy centers on stimulating the innate immune system via toll‐like receptor 9 (TLR9) agonism to drive targeted immune responses while minimizing systemic exposure and toxicity.

The company’s lead product candidate, PDS0108, is an intratumoral TLR9 agonist prodrug currently in Phase 1/2 clinical trials for patients with advanced solid tumors.